Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention

NCT02456740 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
955
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Amgen